The literature for the complete document has been assessed and all chapters of the 2024 PCa Guidelines have been updated. New data have been included in the following sections, resulting in new sections, and new and revised recommendations:
- An update in section 4.4 regarding the 2016 Cambridge Prognostic Groups.
- Restructure of section 5 – Diagnostic Evaluation to separate biopsy indication, biopsy strategy and biopsy approach.
- Incorporation of new text and references throughout section 5 including a new subsection 5.3.4 on tissue samples for homologous recombination repair (HRR)-testing and 5.3.5.7 on Intra-operative assessment of surgical margin status. Update on Table 5.6, Table 5.7, Figure 5.2 and a new section in section 5.5.4 on perilesional biopsy.
- New text additions throughout section 6 with special attention to section 6.1 treatment modalities and new summary of evidence in section 6.2.5 on active surveillance strategy as well as 6.4.2 on controversies in the definitions of clinically relevant PSA relapse.
- Substantial text additions to section 6.7.6.6 on combinations with PARP inhibitors.
- New recommendation in section 6.3.2.5 Guidelines for the treatment of intermediate-risk disease regarding active surveillance and radiotherapeutic treatment.
- New recommendations in section 6.3.3.4 Guidelines for radical and palliative treatment of high-risk localised disease and for Pelvic lymph node dissection (PLND) and radiotherapeutic treatment.
- New recommendations in section 6.7.13 on the Guidelines for systemic treatments of castrate resistant disease.
- Small amendments to Figure 6.4 and Figure 6.5
- New subsection 8.2.1 on active surveillance and 8.2.5.8 on osteonecrosis during bisfosfonates or denosumab as well as substantial addition of text to section 8.3.1 and 8.3.2.